The University of California, Davis (UCD) Cancer Clinical Trials Program represents a multidisciplinary team integrating the clinical and research expertise of physicians, pharmacologists, molecular biologists, biostatisticians, research nurses and clinical research coordinators for the NCI-designated UCD Cancer Center and its outreach network facilities, the Northern California VA Health Care System, and an extensive community affiliate program. As documented in this proposal, during the last grant cycle UCD continued to have a strong presence in both the science and patient accrual objectives of SWOG. During the grant cycle (January 2004 - December 2008), UCD and its affiliates led SWOG with 342 new patient registrations. Scientific input in SWOG is demonstrated by strong contributions to study design and coordination, as well as by positions of Group leadership and provision of special expertise and resources. Pilot studies at UCD and preclinical data generated by UCD investigators continue to be translated into SWOG trials. Even greater scientific input is anticipated during the next grant cycle due to key recruitments and continued growth of the UCD Cancer Center. The overall objective of this proposal is to improve cancer outcomes by providing protocol-governed interventions to the North-Central California population.
Specific aims are as follows: Provide a scientific resource to SWOG in correlative science, thereby facilitating translation of laboratory discoveries into hypothesis-driven clinical research. Provide clinical trials sophistication in the design and conduct of SWOG studies, emphasizing institutional strengths in Urologic Oncology and Lung Cancer. Improve access to NCI-sponsored clinical trials, including cancer control and prevention studies, to the community at large, emphasizing underserved rural and minority patient populations in our area. These goals will be addressed by a multidisciplinary team of investigators with considerable experience and expertise in the conduct of cancer clinical research, an already proven track record in SWOG, and the dedicated resources of UCD's NCI-designated Cancer Center. Thus, UCD is particularly well positioned to take full advaritage of new opportunities for facilitating and coordinating SWOG-related clinical research studies in North-Central California.
Relevance of this UCD SWOG application to public health is demonstrated by the overall mission: to improve cancer outcomes, including cancer control, prevention and treatment, to the North-Central California population. Additionally, this proposal is designed to improve access to NCI-sponsored clinical trials to underserved rural and minority patient populations in our area.
|Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641|
|Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2016) Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer 17:113-8.e1-2|
|Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7|
|Advani, Ranjana H; Hong, Fangxin; Fisher, Richard I et al. (2015) Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. J Clin Oncol 33:1936-42|
|Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2015) Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol 10:110-5|
|Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62|
|Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64|
|Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91|
|Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64|
|Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8|
Showing the most recent 10 out of 129 publications